SELENEX Is now live

SELENEX

Revolutionizing healthcare with AI that's autonomous, personalized, and built to scale.

Our Mission Technology

Where Data Meets
Biological Reality.

Medical Analysis

Multi-modal Fusion

Unifying pathology, radiology, genomics, and multimodal data with AI.

Hover to discover

Multi-modal Fusion

Unifying pathology, radiology, genomics, and multimodal data with AI.

Our AI seamlessly integrates imaging data from CT, MRI, and X-ray with histopathological analysis, creating a unified diagnostic framework that captures the complete clinical picture for each patient.

Deep integration pipeline
Lab Research

SeleneX is advancing the future of healthcare through autonomous AI – built on deep integration of multi-modal patient data, machine learning, statistical reasoning, and scalable models for next-generation diagnosis, personalized interventions, and long-term care.

Precision in every pixel.

SeleneX integrates real-time AI, generative inference, and multi-modal patient data into intelligent systems that support diagnosis, prediction, and personalized care at scale.

Live Inference v2.1
Risk: 94%
Processing...

1. Autonomous Risk Localization Continuous, real-time segmentation and diagnostic scoring during scans — powered by self-improving models trained on generative synthetic cohorts.

Unified Model

2. Multi-modal Predictive Fusion Combining imaging, biomarkers, genomics, and clinical history into a unified latent space — enabling highly personalized and explainable diagnostic decisions.

Patient Data JSON
1 patient_id : "SX-9821" ,
2 biomarkers : {
3 "EGFR" : true ,
4 "KRAS" : false
5 },
6 history_risk : 0.82 ,
7 status : "analyzing"
... stream active

3. Structured Clinical Intelligence Transforming raw clinical notes, EHR records, and biomarker profiles into interpretable, machine-readable vectors for longitudinal modeling and adaptive care.

The Clinical Gap.

THE REALITY
70%
Late Stage Detection

Stage III/IV

Of ovarian cancer cases are detected at late stages, drastically reducing survival rates.

SURVIVAL
<30%
Late-Stage Survival

Survival Rate

Late-stage survival rates are dramatically lower than early detection.

THE PROBLEM
SIGNAL LOST

Silent Signals

Current screening methods fail to capture multimodal signals of early-stage HGSOC.

CRITICAL RISK
Image-Only Diagnosis

Over-Reliance on Imaging

Single-modality approaches miss critical biomarkers, increasing risk of missed diagnoses and patient mortality.

CARE GAP
One-Size-Fits-All

Lack of Personalization

Generic protocols ignore individual patient trajectories, leading to delayed interventions and preventable deaths.

DATA GAP
Demographic Gaps

Data Bias

Scarcity and demographic gaps in available datasets limit AI fairness and accuracy.

THE SOLUTION
Reactive
Predictive

The SeleneX Shift

Moving from reactive standard care to predictive, continuous monitoring.

Platform Overview

What is SeleneX?

AI-Powered Platform

Early Detection & Management of Ovarian Cancer

An innovative AI-driven platform leveraging cutting-edge multimodal data fusion to detect cancer at its earliest, most treatable stages.

20%+

Detection Improvement

100%

Privacy-First Design

CT / MRI

Genomics

EHRs

Symptoms

Multimodal Data Fusion

Imaging, omics, EHRs, and patient-reported data

Proprietary Knowledge Graph

Connecting diverse data sources intelligently

AI Agent Active

Orchestrating progressive data analysis...

Non-invasive analysis complete
Processing biomarkers...

Generative AI Agents

Intelligent orchestration of diagnostic workflows

EHR & Anamnesis

Patient history

Biomarkers

Blood & Urine

Imaging

CT / MRI / US

Advanced

If needed

Progressive Data Escalation

Starting non-invasive, advancing only when necessary — reducing patient burden and healthcare costs

HIPAA GDPR Federated

Privacy-First Design

Federated learning keeps data secure and compliant

Low Risk

Review

Why?

Explainable AI

Transparent decisions clinicians can trust

Simulating...

Digital Twins

Virtual patient models for treatment simulation

Core Technologies

Our Technology Stack

Advanced capabilities powering the next generation of early cancer detection.

Multimodal AI Fusion
PRIMARY

Multimodal AI Fusion

Unified patient view through cross-modal data fusion. Integrating imaging, genomics, EHRs, and patient-reported symptoms into a single intelligent system.

Graph Neural Networks

Proprietary knowledge graph connecting diverse data sources intelligently.

Graph Neural Networks

Federated Learning

Privacy-preserving AI that learns without centralizing sensitive patient data.

Federated Learning

Explainable AI

Transparent reasoning with attention heatmaps and confidence scoring.

Explainable AI

Synthetic Data

Privacy-compliant data generation for rare cancer subtypes using diffusion models.

Synthetic Data

Digital Twins

Patient-specific virtual models for therapy forecasting and in silico testing.

Digital Twins
What We Built

Synthetic Data
Generation Engine

The largest curated ovarian cancer data library available today. Combining ultrasound datasets, biomarker tables, omics matrices, and clinical schemas into one unified resource.

Real Medical Data

Learns patterns from actual clinical records

Synthetic Patients

Generates realistic patient profiles

AI Training Safe

Perfect for fairness testing

Zero Exposure

No patient identity leakage

sdge_pipeline.py
Running...
INPUT
CT/MRI
Genomics
EHRs
PROCESS
CTGAN + Diffusion Model
OUTPUT
Synthetic Patient Records Growing

99.2%

Fidelity Score

0.01%

Privacy Risk

<2min

Generation Time

From Data to Deep Insight.

SeleneX transforms fragmented medical data into a unified, predictive patient view through a 4-step multimodal engine.

Encrypting Data...

Secure Intake & Encoding

GDPR CompliantEnd-to-End EncryptionVectorization

Transforming diverse patient data into secure, computable vectors. We ensure 100% data sovereignty with on-premise encryption before any analysis begins.

The Proof

Clinical Evidence & Validation

Rigorous validation across diverse populations and clinical settings ensures reliability when it matters most.

Global Expertise

15+ PhDs

Growing Team

AI, oncology, radiology, pathology & bioinformatics

Data Modalities

Multimodal

5+

Countries

Global

7

Auto-indexing enabled • 4 regions Latency: 37ms

Diagnostic Pathway

AI Optimized
PT

Patient Scan

CT_Thorax

ID: #8921

Processing

AI Bridge
DR

Oncologist Review

In Review

Priority: High

Confidence: 98%

False Positive Rate: 0.18%

Symptom Analysis

Week 34

Anomaly Detected

Unusual spike in reported fatigue.

HSM Shards Active

Privacy Vault

Distribute signing authority across regions securely.

Tamper feed Secure

Data Sources

Research Datasets
MLTR

Multimodal Clinical Registry

Expanding clinical-imaging pairs

Validated
PKG

Knowledge Graph (PKG)

Proprietary Ovarian Pharmacogenomics

Proprietary

Data Pipeline

Training on validated public datasets.

Global Impact

Scale & Precision.

A vast, living network of intelligence. Every case analyzed refines the global model — transforming individual data points into shared diagnostic intelligence.

Large-Scale Synthetic Simulation

A continuously expanding foundation of synthetic patient trajectories used for research, model development, and validation. Hundreds of thousands of generated trajectories across modalities.

Noise-Aware Diagnostics

Reducing diagnostic noise by contextualizing anomalies across multimodal patient data — minimizing unnecessary interventions.

Earlier Signal Detection

Designed to surface risk indicators earlier in clinical workflows, where time-sensitive decisions matter most.

Global, Cross-Disciplinary Expertise

A team of 15+ PhDs and clinical, technical, and commercial experts from the U.S., Canada, Armenia, Portugal, Spain, Germany, the Netherlands, Brazil, and Mexico — spanning oncology, bioinformatics, AI, radiology, and regulatory science. United by a mission to build trustworthy, high-impact AI in healthcare.

Human-Centered Trust

Built to support clinicians with explainable, transparent AI — augmenting decision-making rather than replacing it.

Validation in Progress

Models developed and evaluated across diverse datasets, with ongoing validation across populations and clinical settings. Built with validation pathways aligned to clinical and regulatory standards.

Cross-Modality Coverage

Designed to reason across imaging, biomarkers, clinical history, and emerging data modalities.

Engineered for Hospitals

Seamless integration with hospital IT infrastructure — empowering diagnostics and care pathways without disrupting existing workflows.

Efficient Inference

Optimized for responsive, real-time assistance in clinical settings. Supports low-latency risk scoring, scan interpretation, or triage, depending on local setup.

Privacy-First & Regulation-Ready

Designed to meet the highest data protection standards: HIPAA (US), GDPR (EU), and privacy-preserving architectures for hospital-grade deployments — including on-premise and hybrid options.

Federated Learning–Ready

Enables decentralized collaboration: hospitals can contribute to global model improvement without sharing sensitive patient data.

Synthetic Data Engine (SDGE)

SeleneX includes a built-in Synthetic Data Generation Engine to safely simulate diverse patient populations across imaging, biomarkers, clinical variables, and omics. This unlocks safer model prototyping, auditing, and federated learning — even in data-scarce or privacy-sensitive environments.

Toward the World’s Largest Cancer Intelligence Catalog

SeleneX is designed to integrate real-world, multi-institutional datasets — including public cohorts (e.g., TCGA, MIMIC-IV) and curated hospital data — into a continually evolving, privacy-safe catalog of cancer knowledge.

Our Story

Built for a Purpose

The Origin

SeleneX was born from a shared conviction: that high-quality, personalized healthcare should not be a privilege of access, geography, or institution — and that AI, when designed with care and clinical depth, can radically expand the reach and equity of diagnostics and treatment.

The Team

Founded in 2025, SeleneX brings together a multidisciplinary, globally distributed team united by a clear mission to transform early cancer detection through multimodal AI.

"
"

To build the AI systems that will power intelligent, personalized, and autonomous care pathways — grounded in real-world clinical data, rigorous science, and human trust.

Our Mission

Founding Team

Meet the Founders

Together, they bring a rare combination of AI systems engineering, global health policy, and deep regulatory awareness.

Tatev Aslanyan

Tatev Aslanyan

🇦🇲 🇺🇸 🇳🇱 🇬🇧 🇮🇹 🇨🇦

CEO & Chief AI Architect

10+ years in AI, econometrics, and data science, with international leadership across the Netherlands, UK, Italy, Canada, and the U.S.

Directs SeleneX's systemic AI architecture, ethical governance, and global clinical partnerships.

First-authored publications in machine learning and AI, with contributions to scientific writing and academic research that bridge theory and clinical application.

Erasmus University Rotterdam • Tilburg University
AI Engineering Data Science ML Ops Deep Learning Research
Vahe Aslanyan
Technical Lead

Vahe Aslanyan

🇦🇲 🇺🇸 🇳🇱 🇨🇦

CTO & Co-Founder

9+ years in advanced AI/ML system architecture, large-scale agent deployment, and robust cybersecurity practices.

Lead architect of SeleneX's multi-modal fusion engines, autonomous AI agents, and production-grade RAG systems.

Active contributor to open-source AI infrastructure, with a focus on building scalable, secure systems for healthcare applications.

Computer Science, UBC (Dean's Honours)
Harvard Business School Executive Education
Software Engineering Infrastructure AI Research Cybersecurity

Born from a Shared Purpose

Tatev and Vahe Aslanyan founded SeleneX with a singular conviction: that decoding biology requires not just data, but a fundamental rethinking of how intelligence scales. Coming from distinct worlds—econometrics and high-performance engineering—they united to build the infrastructure for the next century of healthcare.

Hiring in London & Tokyo

A Truly Global & Cross-Disciplinary Team

From machine learning engineers to clinical researchers, our diversity is our strength. Operating across 3 continents to solve healthcare's hardest problems.

Global Operations Map

Global Operations

Hubs in San Francisco, London, and Amsterdam driving 24/7 innovation cycles across three distinct timezones.

Core

35%

AI & Machine Learning

Bio

20%

Computational Biology

Med

MD+

Clinical Strategy

15+

Nationalities

R&D

15+

PhDs & Researchers

Join the Mission

Help us decode the future of human health. We are looking for extraordinary talent to join our global hubs.

Our Expertise

AI/ML engineers, data scientists, and econometricians

Oncologists, radiologists, surgeons, and infectious disease specialists

Bioinformaticians and omics experts

Clinical researchers, regulators, and commercialization leads

Academic professors and institutional collaborators

Global Presence

🇦🇲 Armenia 🇨🇦 Canada 🇺🇸 United States 🇵🇹 Portugal 🇪🇸 Spain 🇩🇪 Germany 🇺🇦 Ukraine 🇳🇱 Netherlands

"Science knows no borders—and neither does our mission."

Global Validation

Scientific & Clinical Expert Council

SeleneX is supported by a Scientific & Clinical Expert Council of over 15 senior researchers, physicians, and professors—each with 15–20+ years of experience in key areas of medicine and health technology.

Their guidance anchors our work in real clinical needs, safety, and scientific rigor.

This council provides clinical depth, validation oversight, and alignment with evolving global regulatory standards—ensuring our technologies remain clinically relevant and future-proof.

Oncology, gynecologic surgery, and urology

Ukraine, Canada, Armenia

Radiology and diagnostic imaging

Head of Radiology, Armenia

Pediatric infectious disease

Armenia, the Netherlands

Omics, AI in oncology, and multimodal data fusion

Portugal, U.S.

Clinical trials, digital health regulation, and medical AI

U.S., Canada

The Problem

Why Early Detection Matters

"AI's most profound application in the long-term will be in healthcare — especially oncology — as AI combined with gene sequencing and CRISPR accelerates medical breakthroughs."

Cathie Wood, ARK Invest CEO • All-In Summit 2025

71% of ovarian-cancer cases are diagnosed at a late stage (Stage III–IV).

Target Ovarian Cancer • Key facts and figures

"5-year survival drops from ~92% (localized) to ~32% (distant). Stage is destiny."

American Cancer Society • SEER 2015–2021

AI support increased breast-cancer detection by 17.6% (6.7 vs 5.7 per 1,000) without worsening recall rates.

Eisemann et al. • Nature Medicine (2025)

"Ovarian cancer is usually found late: 55% diagnosed after metastasis; only 20% caught while localized."

US NCI SEER • Cancer Stat Facts

Medical Scan
Early Detection
Research Lab
AI-Powered
The Opportunity

Moving diagnosis from late to early stage can improve 5-year survival from 32% to 92% — nearly tripling patient outcomes through AI-enabled early detection.